Eli Lilly

LLYPharmaceuticals

Mentions

Podcasts

Episodes

Podcast consensus

Points of consensus

▶Eli Lilly is developing an oral GLP-1 drug for obesity, which is currently undergoing the regulatory approval process and is positioned as a maintenance therapy after injectable treatments. (Claims 28, 32, 34)May 2026

▶The company is pioneering a one-time gene-editing therapy targeting PCSK9 in the liver, designed to permanently lower a patient's LDL cholesterol into the 20-40 mg/dL range. (Claims 8, 13, 19)May 2026

▶Eli Lilly is actively expanding its pipeline through significant acquisitions, including Colonia Therapeutics for its in-vivo CAR-T cancer therapy and three vaccine developers. (Claims 1, 3, 27)May–Jun 2026

▶The company's anti-amyloid medicine for Alzheimer's is a key pipeline asset, capable of slowing cognitive decline by approximately 30% in late-stage patients and supported by the fastest-enrolling prevention study in history. (Claims 9, 14, 22, 24)May 2026

Points of debate

▶There is a significant disparity in Eli Lilly's insulin pricing, where the list price reached $275 per prescription, but the company's net revenue was only $30 to $40 due to the PBM rebate system. (Claims 6, 18)May 2026

▶The efficacy of Eli Lilly's oral obesity maintenance pill shows varied outcomes depending on the prior treatment; patients switching from Wegovy regained an average of two pounds, while those from Zepbound regained about 11 pounds after a year. (Claims 31, 36)

▶Despite Eli Lilly launching a lower-priced authorized generic insulin to improve access, no insurance formularies covered it in its first year, limiting its availability to cash-paying patients and highlighting a disconnect in the healthcare system. (Claim 7)May 2026

▶While an ICER analysis found Eli Lilly's Zepbound to be highly cost-effective, the company reportedly made a deal with the Trump administration to price tirzepatide at a significantly lower $50 for Medicare patients, indicating tension between value-based pricing and government negotiations. (Claims 2, 12, 20)May 2026

Key themes

▶Dominance in Metabolic DiseaseMay 2026

Eli Lilly has established a commanding position in the healthcare market, largely driven by its GLP-1 franchise. Its drug Mounjaro (tirzepatide) has become the world's highest-grossing prescription medication, and its GLP-1 medicine has shown a 94% reduction in the risk of progressing from pre-diabetic to diabetic. The company is building on this success with a pipeline that includes an oral GLP-1 drug, though it faces competition from rivals like Novo Nordisk and Pfizer.

Eli Lilly's valuation and growth are heavily tied to its GLP-1 portfolio, making pipeline execution for next-generation obesity treatments and defense against competitors critical for sustaining its market leadership.

▶Pioneering Next-Generation Therapeutic PlatformsMay–Jun 2026

Beyond metabolic diseases, Eli Lilly is investing heavily in potentially curative or transformative therapies. This includes a one-time PCSK9 gene-editing therapy to permanently lower LDL cholesterol and a novel in-vivo CAR-T therapy for cancer acquired from Colonia. The company is also a leader in Alzheimer's research, with an anti-amyloid medicine that slows cognitive decline and a prevention study that was the fastest-enrolling in history.

This strategic focus on high-risk, high-reward areas like gene editing and Alzheimer's indicates a long-term strategy to create new markets and secure durable revenue streams beyond its current blockbusters.

▶Navigating US Drug Pricing and AccessMay 2026

Eli Lilly operates within a complex and contentious US drug pricing environment. The company has faced scrutiny for high insulin list prices ($275), while its net revenue is a fraction of that due to PBM rebates. In response, it has introduced lower-priced generics and demonstrated the cost-effectiveness of its newer drugs like Zepbound, which an ICER analysis found to be highly effective for its cost.

Eli Lilly's experience with insulin pricing highlights the systemic challenges in the market, forcing the company to use data-driven cost-effectiveness arguments and innovative distribution models like Lilly Direct to justify prices and manage public perception.

▶Aggressive Growth Through Strategic M&A

Eli Lilly is leveraging its strong financial position to acquire external innovation and bolster its pipeline. The company has made multi-billion dollar deals to buy Colonia Therapeutics for its cancer therapy platform and three separate vaccine developers. These acquisitions provide access to new technologies and de-risk the company's internal R&D efforts.

The company's M&A strategy is focused on acquiring assets in high-growth therapeutic areas, signaling an intent to diversify its revenue base and quickly build expertise in fields like oncology and immunology.

Source episodes

Timeline

2022

Eli Lilly's revenue was reported at $28 billion, providing a baseline for its subsequent explosive growth. (Claim from Paul Sweeney)

First year of generic insulin launch

The company's lower-priced authorized generic insulin was launched but failed to gain traction with insurers, as no formularies covered it, limiting its impact on affordability. (Claim 7)

Present Day (relative to podcasts)

Discourse centers on Eli Lilly's massive success, having crossed a $1 trillion market valuation. Projections for the current year's revenue have soared to $85 billion, driven by the success of Mounjaro, which surpassed Keytruda as the world's top-selling drug. (Quotes from Adam Feuerstein, Paul Sweeney; Claim 5)

Later this year (speculative)

Anticipation is building for the release of new clinical data for Eli Lilly's anti-amyloid Alzheimer's medicine, with experts predicting it will show 'dramatic protective effects' when used early. (Claim 25)

November 2025

A reported deal with the Trump administration is mentioned, which would set the price of tirzepatide at $50 for Medicare patients, highlighting future pricing pressures. (Claim 2)

Q1 2026 (speculative)

Analysts predict that Eli Lilly's oral GLP-1 drug will receive FDA approval, likely in March, marking the company's entry into the oral obesity treatment market. (Claim 30)

Suggested prompts

How will Eli Lilly's direct-to-consumer strategy with Lilly Direct impact the role of PBMs and its net pricing for key drugs like Zepbound? &nearr;What are the primary risks to Eli Lilly's dominance in the obesity market, considering the competitive pipeline from Novo Nordisk, Pfizer, and Viking Therapeutics? &nearr;Given the mixed maintenance results for the oral obesity pill, what is the likely market positioning and adoption rate for patients switching from different injectable GLP-1s? &nearr;How might the success of the one-time PCSK9 gene-editing therapy disrupt the long-term revenue model for chronic cardiovascular medications? &nearr;

Key concepts

GLP-1 / Obesity Treatment 7 ep Drug Pricing / PBMs 2 ep Alzheimer's Disease 2 ep M&A / Acquisitions 3 ep Clinical Trials / R&D Efficiency 2 ep Cancer Therapy / CAR-T 3 ep Financial Performance / Valuation 3 ep Gene Editing / PCSK9 1 ep

Notable quotes

“one of the highlights of this year was Eli Lilly crossing the $1 trillion market value threshold. you know, they are the first healthcare company to achieve a $1 trillion valuation.”

Adam Feuerstein · The Year in Biotech and What’s Ahead for 2026

“We've got amazing GLP-1 medicines that I started with that from clear data out of Eli Lilly show a 94% reduction in your risk of moving from being pre-diabetic to diabetic.”

Alex Karnal · Designing the Modern Health Stack | Alex Karnal

“today we've got some amazing medicines that are both Biogen and Eli Lilly that if you are late in the disease progression of Alzheimer's, you can start to slow the decline. We can slow that decline by about 30%.”

Alex Karnal · Designing the Modern Health Stack | Alex Karnal

“Eli Lilly is upending the traditional model by selling directly to their consumers over the internet with Lilly Direct, rather than through the traditional middlemen.”

Stripe Host · Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma

Report last updated: Jun 10, 2026

Get started free

Back to Entities Intelligence Report